Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects

References

• caac.pdf [Internet]. [cited 2019 Aug 3]. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21492
   Google Scholar
• Globocan 2018: India factsheet [Internet]. India Against Cancer. 2018 [cited 2019 Aug 3]. Available from: http://cancerindia.org.in/globocan-2018-india-factsheet/
   Google Scholar
• Molin Y, Fayette J. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs. 2011 Aug;22(7):621–625.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol. 1992 Aug 1;10(8):1245–1251.
   PubMed Web of Science ®Google Scholar
• Schornagel JH, Verweij J, de Mulder PH, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European organization for research and treatment of cancer head and neck cancer cooperative group study. J Clin Oncol. 1995 Jul 1;13(7):1649–1655.
   PubMed Web of Science ®Google Scholar
• Wittes RE, Cvitkovic E, Shah J, et al. CIS-dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep. 1977 Jun;61(3):359–366.
   PubMedGoogle Scholar
• Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15(3):283–289.
   PubMed Web of Science ®Google Scholar
• Kish JA, Weaver A, Jacobs J, et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer. 1984 May 1;53(9):1819–1824.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol Off J Am Soc Clin Oncol. 1992 Feb;10(2):257–263.
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC head and neck cancer cooperative group. Ann Oncol Off J Eur Soc Med Oncol. 1994 Jul;5(6):521–526.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an eastern cooperative oncology group trial (PA390). Cancer. 1998 Jun 1;82(11):2270–2274.
   PubMed Web of Science ®Google Scholar
• Adamo V, Ferraro G, Pergolizzi S, et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 2004 May;40(5):525–531.
   PubMed Web of Science ®Google Scholar
• Basaran M, Bavbek SE, Güllü I, et al. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother Florence Italy. 2002 Apr;14(2):207–213.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the eastern cooperative oncology group. J Clin Oncol [Internet]. 2016 Sep 21 [cited 2019 Aug 4]. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2005.01.057
   Google Scholar
• Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol [Internet]. 2016 Sep 21 [cited 2019 Aug 4]. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.1996.14.5.1672
   Google Scholar
• Schöffski P, Catimel G, Planting AST, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neckResults of a phase II study of the EORTC early clinical studies group. Ann Oncol. 1999 Jan 1;10(1):119–122.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695–1704.
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer [Internet]. 2009 [cited 2019 Aug 4]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa070956?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov
   Google Scholar
• Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000 Apr;23(2):128–131.
   PubMed Web of Science ®Google Scholar
• Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001 Apr 1;91(7):1316–1323.
   PubMed Web of Science ®Google Scholar
• Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr 1;16(4):1325–1330.
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Dec 1;23(34):8646–8654.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116–1127.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010 Aug;7(8):455–465.
   PubMed Web of Science ®Google Scholar
• Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004 Apr;31(2 Suppl 7):2–11.
   PubMed Web of Science ®Google Scholar
• Pai RB, Lalitha RM, Pai SB, et al. Analysis of in vitro and in vivo sensitivity of oral cancer cells to methotrexate. Exp Oncol. 2009 Jun;31(2):118–120.
   PubMedGoogle Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915–1928.
   PubMed Web of Science ®Google Scholar
• WHO | WHOQOL: measuring quality of life [Internet]. WHO. [cited 2019 Dec 15]. Available from: https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/
   Google Scholar
• Murphy BA, Ridner S, Wells N, et al. Quality of life research in head and neck cancer: a review of the current state of the science. Crit Rev Oncol Hematol. 2007 Jun;62(3):251–267.
   PubMed Web of Science ®Google Scholar
• Rogers SN, Ahad SA, Murphy AP. A structured review and theme analysis of papers published on “quality of life” in head and neck cancer: 2000–2005. Oral Oncol. 2007 Oct;43(9):843–868.
   PubMed Web of Science ®Google Scholar
• Ojo B, Genden EM, Teng MS, et al. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol. 2012 Oct;48(10):923–937.
   PubMed Web of Science ®Google Scholar
• List MA, Stracks J. Evaluation of quality of life in patients definitively treated for squamous carcinoma of the head and neck. Curr Opin Oncol. 2000 May;12(3):215–220.
   PubMed Web of Science ®Google Scholar
• Patil V, Joshi A, Noronha V, et al. Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncol. 2016;63:10–15.
   PubMed Web of Science ®Google Scholar
• Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010 Oct;21(10):1967–1973.
   PubMed Web of Science ®Google Scholar
• Patil V, Joshi A, Noronha V, et al. Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian J Cancer. 2018;7(4):249–253.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Noronha V, Joshi A, Marfatia S, et al. Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2016 Apr;24(4):1595–1602.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer. J Clin Oncol. 2019 Nov 10;37(32):3032-3041. DOI: 10.1200/JCO.19.01076.
   Google Scholar
• Pêtre A, Dalban C, Karabajakian A, et al. Carboplatin in combination with weekly paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget. 2018 Apr 24;9(31):22038–22046.
   PubMedGoogle Scholar
• Moosmann P, Egli F, Stahel RA, et al. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie. 2003 Dec;26(6):568–572.
   PubMedGoogle Scholar
• Gedlicka C, Formanek M, Selzer E, et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology. 2002;63(2):145–150.
   PubMed Web of Science ®Google Scholar
• Glisson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol Off J Am Soc Clin Oncol. 2002 Mar 15;20(6):1593–1599.
   PubMed Web of Science ®Google Scholar
• Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol Off J Eur Soc Med Oncol. 2012 Apr;23(4):1016–1022.
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol Off J Eur Soc Med Oncol. 2015 Sep;26(9):1941–1947.
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Mesia R, et al. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019 May 20;37(15_suppl):6002.
   Google Scholar
• Vermorken JB, Psyrri A, Mesía R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol Off J Eur Soc Med Oncol. 2014 Apr;25(4):801–807.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697–710.
   PubMed Web of Science ®Google Scholar
• Misiukiewicz K, Bonomi M, Demicco E, et al. Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck. Ann Oncol Off J Eur Soc Med Oncol. 2014 Aug;25(8):1667–1668.
   PubMed Web of Science ®Google Scholar
• Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119(2):153–159.
   PubMed Web of Science ®Google Scholar
• Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2017 May 10;35(14):1542–1549.
   PubMed Web of Science ®Google Scholar
• Glück S, Lau H, Mackinnon J, et al. Metronomic therapy in recurrent and metastatic chemoresistant SCCHN: data from a pilot study. Biomed Pharmacother. 2005 Oct;1(59):S319.
   Google Scholar
• Patil. Metronomic chemotherapy in advanced oral cancers [Internet]. [cited 2019 Aug 12]. Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2012;volume=8;issue=6;spage=106;epage=110;aulast=Patil#ref13
   Google Scholar
• Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. 2015 Mar 1;51(3):279–286.
   PubMed Web of Science ®Google Scholar
• Rischin D, Harrington KJ, Greil R, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019 May 20;37(15_suppl):6000.
   Google Scholar
• de Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res. 2012 Apr 15;18(8):2336–2343.
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol Off J Am Soc Clin Oncol. 2004 Jan 1;22(1):77–85.
   PubMed Web of Science ®Google Scholar
• Kirby AM, A’Hern RP, D’Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006 Mar 13;94(5):631–636.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol Off J Am Soc Clin Oncol. 2003 May 15;21(10):1980–1987.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res. 2005 Dec 1;11(23):8418–8424.
   PubMed Web of Science ®Google Scholar
• Stewart JSW, Cohen EEW, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [Corrected]. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Apr 10;27(11):1864–1871.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol Off J Eur Soc Med Oncol. 2014 Sep;25(9):1813–1820.
   PubMed Web of Science ®Google Scholar
• Machiels J-PH, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-head & neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May 1;16(5):583–594.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Licitra LF, Fayette J, et al. Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-head & neck 1 (LUX-H&N1). J Clin Oncol. 2015 May 20;33(15_suppl):6023.
   Web of Science ®Google Scholar
• Kushwaha VS, Gupta S, Husain N, et al. Gefitinib, methotrexate and methotrexate plus 5-fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. Cancer Biol Ther. 2015;16(2):346–351.
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Apr 10;31(11):1405–1414.
   PubMed Web of Science ®Google Scholar
• León X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol R Coll Radiol G B. 2005 Sep;17(6):418–424.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based the. J Clin Oncol. 2007 Jun 1;25(16):2171–2177.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Tourneau CL, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 Jan 12;393(10167):156–167.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian J Med Paediatr Oncol. 2015 Jul 1;36(3):161.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer. Indian J Cancer. 2017 Jan 1;54(1):25.
   PubMed Web of Science ®Google Scholar
• Vlaming MLH, van Esch A, Pala Z, et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther. 2009 Dec;8(12):3350–3359.
   PubMed Web of Science ®Google Scholar
• Shen B, Dong P, Li D, et al. Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp Ther Med. 2011 Nov;2(6):1151–1157.
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2014 Feb;9(2):154–162.
   Google Scholar
• Ignacio DN, Griffin JJ, Daniel MG, et al. An evaluation of treatment strategies for head and neck cancer in an African American population. West Indian Med J. 2013 Jul;62(6):504–509.
   PubMed Web of Science ®Google Scholar